{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:16:26Z","timestamp":1758845786557,"version":"3.44.0"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Persons co\u2010infected with hepatitis C virus and hepatitis B virus (HCV\u2010HBV) are at increased risk of developing liver disease compared with mono\u2010infected individuals. In Georgia, all patients undergoing hepatitis C treatment are eligible for free testing for hepatitis B surface antigen (HBsAg). However, further hepatitis B evaluations and treatment are not free. We explored demographic and clinical characteristics associated with HCV\u2010HBV co\u2010infection among persons treated for HCV infection. Persons aged \u2265\u200918\u2009years with HCV infection who initiated HCV treatment during 2017\u20132023 were included. Patients were grouped as HCV mono\u2010infected, HCV\u2010HBV co\u2010infected (HBsAg positive), and HBV exposed (total HBV core antibody positive, HBsAg negative). We present descriptive analysis and adjusted prevalence ratios (aPR) with 95% confidence intervals (95% CI). Of 54,994 adults treated for hepatitis C, 68.1% had HCV mono\u2010infection, 29.3% were previously exposed to HBV, and 2.6% had HCV\u2010HBV co\u2010infection. Persons who were aged 18\u201345\u2009years (aPR: 1.75, 95% CI: 1.48\u20132.08), male (aPR: 1.38, 95% CI: 1.11\u20131.71), reported ever injecting drugs (aPR: 1.40, 95% CI: 1.19\u20131.66), had end\u2010of\u2010HCV treatment, alanine transaminase (ALT) levels &gt;\u200980\u2009IU\/L (aPR: 2.14, 95% CI: 1.40\u20133.29) and did not achieve hepatitis C cure after treatment (aPR: 1.83, 95% CI: 1.13\u20132.95) were more likely to have HCV\u2010HBV co\u2010infection vs. HCV mono\u2010infection. Patients who did not achieve cure and had persistently higher ALT levels after hepatitis C treatment were more likely to have HCV\u2010HBV co\u2010infection. Expanded access to hepatitis B care and treatment, and co\u2010management of HBV infection along with HCV treatment in co\u2010infected persons are needed to improve clinical outcomes.<\/jats:p>","DOI":"10.1111\/jvh.70067","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:20:28Z","timestamp":1756988428000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co\u2010Infection, Georgia, 2017\u20132023"],"prefix":"10.1111","volume":"32","author":[{"given":"Senad","family":"Handanagic","sequence":"first","affiliation":[{"name":"Division of Viral Hepatitis U.S. Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5772-7046","authenticated-orcid":false,"given":"Shaun","family":"Shadaker","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis U.S. Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davit","family":"BaliashvilI","sequence":"additional","affiliation":[{"name":"The Task Force for Global Health  Tbilisi Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina Tskhomelidze","family":"Schumacher","sequence":"additional","affiliation":[{"name":"The Task Force for Global Health  Tbilisi Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige A.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis U.S. Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania A.","family":"Tohme","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis U.S. Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Butsashvili","sequence":"additional","affiliation":[{"name":"Health Research Union (HRU)  Tbilisi Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002995"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14455"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.025"},{"issue":"2","key":"e_1_2_10_5_1","first-page":"221","article-title":"The Spectrum of HBV\/HCV Coinfection: Epidemiology, Clinical Characteristics, Viral Interactions and Management","volume":"28","author":"Konstantinou D.","year":"2015","journal-title":"Annals of Gastroenterology"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102012\u2010304370"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031183"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010014\u20103486\u20107"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)31865\u20108"},{"key":"e_1_2_10_10_1","unstructured":"World Health Organisation \u201cGuidelines for the Prevention Care and Treatment of Persons With Chronic Hepatitis B Infection (Issue April) \u201d(2024) https:\/\/www.who.int\/publications\/i\/item\/9789240090903."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2016.06.006"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.027"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17\u20100377"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29109"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/v12070741"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6428a2"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010019\u20104741\u20105"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.019"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560\u20107917.ES.2023.28.30.2200837"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072\u2010009\u20109147\u20109"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/FVIRO.2021.742722"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.138"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad182"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262935"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104\u2010020\u201005173\u20104"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9060432"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010018\u20102988\u2010x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad064"},{"key":"e_1_2_10_31_1","unstructured":"Health Research Union Integrated Bio\u2010Behavioral Surveillance Survey Among People Who Inject Drugs Risk Behaviors and HIV Prevalence Trends in Target Groups With High Risk of Study Report(2022) https:\/\/toka.ge\/theproject_cdn\/files\/hru\/ck\/ibss\u2010report\u2010final\u2010eng\u2010final\u201015\u201003\u20102023.pdf."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102893"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2021.03.017"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:15:34Z","timestamp":1758798934000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/jvh.70067"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70067","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"2025-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70067"}}